Form 4: Pharvaris Exec Anne Lesage Trades Shares

Pharvaris N.V. executive Anne Lesage reported transactions involving company common stock, including the exercise of stock options and subsequent sales.

Summary

• Anne Lesage, Chief Early Development at Pharvaris N.V., executed a Rule 10b5-1 trading plan on June 25, 2026.
• This plan involved the exercise of stock options and the sale of common stock.
• Specifically, 1,400 shares were acquired at $2.59 and 900 shares at $8.05.
• Additionally, 2,300 shares were sold at a weighted average price of $35.1194 and another 2,300 shares at $35.1242.
• Following these transactions, Lesage beneficially owns 57,850 shares directly and 131,669 shares indirectly through GrayMatters Consulting BVBA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves stock sales by an executive, the transactions were conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns about insider trading.

Positives

• Execution of a pre-planned trading strategy (Rule 10b5-1) indicates disciplined financial management.
• The sale prices achieved ($35.00 to $35.30 range) suggest a favorable market valuation at the time of the transactions.
• Continued beneficial ownership, both direct and indirect, indicates ongoing commitment to the company.

Negatives

• Sale of company stock by an executive can sometimes be perceived negatively by the market, though this was a planned transaction.
• The exercise of options and subsequent sale reduces the executive's direct equity stake.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The primary risk associated with such transactions is the potential for negative market perception, despite being part of a pre-arranged plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions.

Management Comments

• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan.
• The sales prices for the transactions ranged from $35.00 to $35.30.
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by an executive like Anne Lesage is a common practice to manage personal stock sales in a way that avoids accusations of insider trading, especially in the biopharmaceutical sector where stock prices can be volatile due to clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if planned, may lead to short-term market scrutiny. However, the use of a 10b5-1 plan is designed to mitigate concerns about insider trading.
• Employees: May view executive stock sales as a signal, though the planned nature of this transaction should provide some reassurance.
• Creditors: No direct impact expected from this type of filing.

Next Steps

• The reporting person may provide further details on individual sale prices upon request from the SEC, issuer, or security holders.
• Continued monitoring of Pharvaris N.V.'s stock performance and future insider transactions.

Key Dates

Keywords

Pharvaris N.V., PHVS, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Anne Lesage, Beneficial Ownership, Securities Transaction